Hans Schikan, CEO of Prosensa, on Rare Disease Drug Development

BIO Praises Final Passage of Patent Reform Legislation

  • Contact: Stephanie Fischer
  • Phone: 202-312-9263
  • Email: sfischer@bio.org
  • Recommend
  • Tweet
  • Print
  • Email

Washington, D.C. (September 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage of The Leahy-Smith America Invents Act, H.R. 1249, by the U.S. Senate:

The report, recently published in its second edition, was authored by Scott Gottlieb, MD, of the American Enterprise Institute, and Matthew B. Wheeler, PhD, of the Institute for Genomic Biology, University of Illinois at Urbana-Champaign.
  • Recommend
  • Tweet
  • Print
  • Email
Bill Gates has been an ally in our efforts to increase access to medicines in developing countries.
Vaccination
Gates Foundation
  • Recommend
  • Tweet
  • Print
  • Email
  • Recommend
  • Tweet
  • Print
  • Email

BIO Thanks Senate Judiciary Leaders for Advancing Patent Reform

  • Contact: Contact Stephanie Fischer
    202-312-9263 or sfischer@bio.org
  • Recommend
  • Tweet
  • Print
  • Email

Washington, D.C. (March 4, 2010) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the manager’s amendment released today by Senate Judiciary Committee Chairman Patrick Leahy (D-VT):

Patent Law Harmonization

I'm writing on  behalf of the Biotechnology Industry Organization (BIO) in response to your invitation for public comments on questions pertaining to international efforts t0 harmonize substantive requirements of patient laws, dated May 3, 2007 (72 FR 24566). BIO is a trade association representing more than 1100 companies and entities focused on research, development commercialization of inventions in the field of Biotechnology.

First-In-Man Study of the COBRA PzF™ Coronary Stent Shows Promising Results Highlighted by Short, 30-Day Dual-Antiplatelet Therapy and Low, 3% TLR Rate

WASHINGTON--(BUSINESS WIRE)--CeloNova BioSciences announces First-in-Man clinical trial results found its COBRA PzF™ coronary stent system a safe/effective routine treatment for real-world and complex heart disease patients.

Feed Date: 
September 16, 2014

Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq™ (belinostat) for Injection with Patent Term Adjustment till 2027

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Announces Issue of a New Patent for Beleodaq(TM) (belinostat) for Injection with Patent Term Adjustment till 2027

Feed Date: 
September 16, 2014